Our Company History
Belhaven was founded in 2021 in Raleigh, North Carolina, with initial funding from local angels and support from the North Carolina Biotechnology Center. This funding enabled the initial formulation work to identify a lead formulation for NasdepiTM and confirmatory nonclinical studies in animal models.
In the second half of 2022, Belhaven successfully completed a pre-IND meeting with the US FDA confirming the development program requirements for NasdepiTM. Belhaven expanded its team to support the transition from research to clinical development and expansion of the product portfolio.